Choline magnesium trisalicylate: comparative pharmacokinetic study of once-daily and twice-daily dosages.
This randomized crossover study compared the pharmacokinetics of choline magnesium trisalicylate tablets administered once daily (3000 mg of salicylate) or twice daily (1500 mg of salicylate) for six d. Serum salicylate levels were measured by HPLC. Mean "trough" concentrations fell within the therapeutic range (5-30 mg/dL) with either regimen and were relatively constant, indicating that the steady state had been reached. The 24-h area under the salicylate curve (AUC0-24 h) after the final 3000-mg salicylate dose averaged about twice the mean 12-h AUC after the last 1500-mg dose, indicating that the two dosing regimens were equally bioavailable. Clinical observations and results of laboratory safety studies indicate that both dosage schedules of the drug are well tolerated. The present findings support the once-daily therapeutic use of choline magnesium trisalicylate.
D000328:Adult; D001682:Biological Availability; D002794:Choline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008297:Male; D012459:Salicylates / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D020156:Salicylic Acid
D012459:Salicylates; C017959:choline magnesium trisalicylate; D002794:Choline; D020156:Salicylic Acid